slow responder to tirzepatide super Tell me in the comments if you're a super responder, responder or non- responder. Hope this explanation helps. 💧💧💧#obesitymedicine #glp1 #glp1forweightloss #glp1medication #obesitydoctor #doctorsofinstagram Tirzepatide's pathway signaling. TZP binds

Patients should not discontinue necessary bone-protective treatments due to concerns about GLP-1 therapy

Once you puncture the vial, the BUD may shorten further

Access to medication is only one part of the equation, weight management today is often difficult to navigate, with patients managing multiple steps across care, medication and lifestyle changes

This is not in dispute

Eli Lillys orforglipron (a non-peptide oral GLP-1) is tracking toward FDA approval by summer 2026 at a similar $149 starting price, and Ro has it listed as Foundayo

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Shares of Eli Lilly and Company (NYSE: LLY), the worlds most valuable pharmaceutical stock, started 2026 in a bad way